Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
Stock Summary
Top Correlated Resources
249420.KS
Top 10 Correlated ETFs
249420.KS
Top 10 Correlated Stocks
249420.KS
Financial details
Company Rating
Buy
Market Cap
1000.43B
Income
-181.37B
Revenue
628.48B
Book val./share
8681.21
Cash/share
3729.7
Dividend
-
Dividend %
-
Employees
1.41K
Optionable
No
Shortable
Yes
Earnings
-
P/E
-5.89
Forward P/E
-
PEG
-0.2
P/S
1.7
P/B
4.6
P/C
10.7
P/FCF
-16.45
Quick Ratio
0.31
Current Ratio
0.99
Debt / Equity
0.21
LT Debt / Equity
0.21
-
-
EPS (TTM)
-2.19K
EPS next Y
-
EPS next Q
-
EPS this Y
480.11%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
NAN%
Revenue last 5Y
3.99%
Revenue Q/Q
0.7%
EPS Q/Q
-230.47%
-
-
-
-
SMA20
41.06%
SMA50
14.42%
SMA100
27.46%
Inst Own
-
Inst Trans
-
ROA
-25%
ROE
-87%
ROC
-0.17%
Gross Margin
37%
Oper. Margin
-11%
Profit Margin
-29%
Payout
-
Shs Outstand
26.79M
Shs Float
15.93M
-
-
-
-
Target Price
-
52W Range
16150.0-79500.0
52W High
-49.81%
52W Low
+147.06%
RSI
61.45
Rel Volume
3.59
Avg Volume
1.09M
Volume
3.93M
Perf Week
-3.86%
Perf Month
49.44%
Perf Quarter
-7.75%
Perf Half Y
-4.32%
-
-
-
-
Beta
1.09667
-
-
Volatility
1872.14%, 5265.65%
Prev Close
6.83%
Price
39900
Change
4.04%
Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2021-12-31
| Metric | History | 2017-12-31 | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Revenue per share | 21.29K | 22.24K | 21.75K | 0 | 17.83K | |
| Net income per share | 917.15 | 561.36 | -565.08 | 0 | -3.17K | |
| Operating cash flow per share | 3.41K | 2.94K | 1.74K | 814.15 | -361.73 | |
| Free cash flow per share | 1.33K | 2.02K | 925.25 | 6.74 | -991.57 | |
| Cash per share | 1.86K | 3.43K | 3.81K | 3.62K | 4.92K | |
| Book value per share | 13.18K | 12.22K | 10.63K | 10.7K | 4.87K | |
| Tangible book value per share | 8.56K | 8.33K | 7.7K | 8.05K | 2.99K | |
| Share holders equity per share | 13.18K | 12.22K | 10.63K | 10.7K | 4.87K | |
| Interest debt per share | 6.2K | 5.91K | 7.19K | 7.01K | 7.53K | |
| Market cap | 544.51B | 425.16B | 365.92B | 440.05B | 1013.33B | |
| Enterprise value | 634.97B | 479.62B | 441.88B | 521.34B | 1103.9B | |
| P/E ratio | 27.44 | 33.42 | -27.22 | 0 | -10.16 | |
| Price to sales ratio | 1.18 | 0.84 | 0.71 | 0 | 1.81 | |
| POCF ratio | 7.39 | 6.38 | 8.85 | 22.72 | -89.15 | |
| PFCF ratio | 18.86 | 9.27 | 16.62 | 2.75K | -32.52 | |
| P/B Ratio | 1.91 | 1.54 | 1.45 | 1.73 | 6.63 | |
| PTB ratio | 1.91 | 1.54 | 1.45 | 1.73 | 6.63 | |
| EV to sales | 1.38 | 0.95 | 0.85 | 0 | 1.97 | |
| Enterprise value over EBITDA | 14.9 | 10.99 | 42.04 | 0 | -11.03 | |
| EV to operating cash flow | 8.61 | 7.2 | 10.68 | 26.92 | -97.12 | |
| EV to free cash flow | 21.99 | 10.46 | 20.07 | 3.25K | -35.43 | |
| Earnings yield | 0.04 | 0.03 | -0.04 | 0 | -0.1 | |
| Free cash flow yield | 0.05 | 0.11 | 0.06 | 0 | -0.03 | |
| Debt to equity | 0.16 | 0.13 | 0.22 | 0.29 | 0.6 | |
| Debt to assets | 0.5 | 0.51 | 0.59 | 0.58 | 0.77 | |
| Net debt to EBITDA | 2.12 | 1.25 | 7.23 | 0 | -0.91 | |
| Current ratio | 1.3 | 1.29 | 1.1 | 1.26 | 0.83 | |
| Interest coverage | 6.76 | 7.9 | -0.26 | 0 | -5.15 | |
| Income quality | 3.72 | 5.24 | -3.08 | 0 | 0.11 | |
| Dividend Yield | 0.01 | 0.02 | 0.02 | 0 | 0 | |
| Payout ratio | 0.27 | 0.62 | -0.64 | 0 | 0 | |
| Sales general and administrative to revenue | 0.04 | 0.03 | 0.03 | 0 | 0.02 | |
| Research and developement to revenue | 0.07 | 0.09 | 0.09 | 0 | 0.17 | |
| Intangibles to total assets | 0.18 | 0.16 | 0.11 | 0.1 | 0.09 | |
| Capex to operating cash flow | -0.61 | -0.31 | -0.47 | -0.99 | 1.74 | |
| Capex to revenue | -0.1 | -0.04 | -0.04 | 0 | -0.04 | |
| Capex to depreciation | -2.43 | -0.88 | -0.69 | -0.69 | -0.68 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 16.49K | 12.42K | 11.63K | 0 | 18.64K | |
| ROIC | 0.06 | 0.07 | 0 | 0 | -0.16 | |
| Return on tangible assets | 0.04 | 0.03 | -0.02 | 0 | -0.16 | |
| Graham Net | -9.67K | -8.1K | -9.85K | -9.25K | -11.22K | |
| Working capital | 47.61B | 47.56B | 21.52B | 48.23B | -62.59B | |
| Tangible asset value | 185.21B | 188.66B | 183.28B | 191.48B | 93.96B | |
| Net current asset value | -74.53B | -77.39B | -126.46B | -117.49B | -246.84B | |
| Invested capital | 0.46 | 0.47 | 0.66 | 0.66 | 1.48 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 31.38B | 28.29B | 37.88B | 35.99B | 37.16B | |
| Average inventory | 74.61B | 71.21B | 79.49B | 89.23B | 85.91B | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 41.69 | 30.2 | 50.91 | 0 | 41.07 | |
| Days of inventory on hand | 93.4 | 78.06 | 89.29 | 0 | 88.48 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 8.75 | 12.09 | 7.17 | 0 | 8.89 | |
| Inventory turnover | 3.91 | 4.68 | 4.09 | 0 | 4.13 | |
| ROE | 0.07 | 0.05 | -0.05 | 0 | -0.65 | |
| Capex per share | -2.07K | -917.47 | -813.5 | -807.41 | -629.84 |
Quarterly Fundamentals Overview
Last date of statement is 2022-09-30 for Q3
| Metric | History | 2021-09-30 | 2021-12-31 | 2022-03-31 | 2022-06-30 | 2022-09-30 |
|---|---|---|---|---|---|---|
| Revenue per share | 0 | 1.36K | 1.52K | 1.54K | 6.11K | |
| Net income per share | 0 | -890.89 | -1.15K | 479.79 | -626 | |
| Operating cash flow per share | 228.23 | -85.92 | -108.96 | -70.79 | -755.79 | |
| Free cash flow per share | -95.72 | -115.72 | -143.02 | -112.82 | -966.53 | |
| Cash per share | 6.83K | 1.47K | 0 | 0 | 3.73K | |
| Book value per share | 10.21K | 1.45K | 1.9K | 2.37K | 8.68K | |
| Tangible book value per share | 7.61K | 893 | 1.97K | 2.43K | 6.53K | |
| Share holders equity per share | 10.21K | 1.45K | 1.9K | 2.37K | 8.68K | |
| Interest debt per share | 9.44K | 2.18K | -1.11K | 891.93 | 7.32K | |
| Market cap | 330.62B | 3535.26B | 7175.73B | 3245.91B | 750.14B | |
| Enterprise value | 411.82B | 3625.83B | 7175.73B | 3245.91B | 880.28B | |
| P/E ratio | 0 | -9.43 | -14.78 | 16.07 | -11.18 | |
| Price to sales ratio | 0 | 24.77 | 44.95 | 19.98 | 4.58 | |
| POCF ratio | 60.9 | -391.04 | -625.92 | -435.77 | -37.05 | |
| PFCF ratio | -145.22 | -290.34 | -476.87 | -273.44 | -28.97 | |
| P/B Ratio | 1.36 | 23.12 | 35.86 | 13.04 | 3.23 | |
| PTB ratio | 1.36 | 23.12 | 35.86 | 13.04 | 3.23 | |
| EV to sales | 0 | 25.41 | 44.95 | 19.98 | 5.38 | |
| Enterprise value over EBITDA | 0 | -31.16 | -30.31 | 19.76 | -66.02 | |
| EV to operating cash flow | 75.86 | -401.06 | -625.92 | -435.77 | -43.47 | |
| EV to free cash flow | -180.89 | -297.78 | -476.87 | -273.44 | -34 | |
| Earnings yield | 0 | -0.03 | -0.02 | 0.02 | -0.02 | |
| Free cash flow yield | -0.01 | 0 | 0 | 0 | -0.03 | |
| Debt to equity | 0.45 | 0.6 | 0 | 0 | 0.21 | |
| Debt to assets | 0.64 | 0.77 | 0.71 | 0.65 | 0.67 | |
| Net debt to EBITDA | 0 | -0.78 | 0 | 0 | -9.76 | |
| Current ratio | 1.35 | 0.83 | 0.91 | 1.14 | 0.99 | |
| Interest coverage | 0 | -6.04 | 0.08 | -0.24 | -8.33 | |
| Income quality | 0 | 0.1 | 0.09 | -0.15 | 1.21 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0.02 | 0.43 | 0.51 | 0.02 | |
| Research and developement to revenue | 0 | 0.21 | 0 | 0 | 0.17 | |
| Intangibles to total assets | 0.1 | 0.09 | 0 | 0 | 0.09 | |
| Capex to operating cash flow | -1.42 | 0.35 | 0.31 | 0.59 | 0.28 | |
| Capex to revenue | 0 | -0.02 | -0.02 | -0.03 | -0.03 | |
| Capex to depreciation | -1.04 | -0.42 | -0.49 | -0.61 | -0.78 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 0 | 5.4K | 7.03K | 5.05K | 11.06K | |
| ROIC | 0 | -0.05 | -0.02 | -0.05 | -0.05 | |
| Return on tangible assets | 0 | -0.15 | -0.17 | 0.07 | -0.03 | |
| Graham Net | -10.12K | -3.35K | -4.86K | -4.55K | -12.17K | |
| Working capital | 81.65B | -62.59B | -29.62B | 43.58B | -2.91B | |
| Tangible asset value | 181.03B | 93.96B | 0 | 0 | 174.92B | |
| Net current asset value | -132.48B | -246.84B | -200.11B | -131.4B | -157.73B | |
| Invested capital | 0.92 | 1.48 | 0 | 0 | 0.83 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 0 | 0 | 0 | 0 | 0 | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 0 | 38.2 | 0 | 0 | 43.98 | |
| Days of inventory on hand | 0 | 82.29 | 0 | 0 | 87.26 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 0 | 2.36 | 0 | 0 | 2.05 | |
| Inventory turnover | 0 | 1.09 | 0 | 0 | 1.03 | |
| ROE | 0 | -0.61 | -0.61 | 0.2 | -0.07 | |
| Capex per share | -323.94 | -29.8 | -34.05 | -42.03 | -210.74 |
Frequently Asked Questions
What is Ildong Pharmaceutical Co., Ltd. stock symbol ?
Ildong Pharmaceutical Co., Ltd. is a US stock and trading under the symbol 249420.KS
What is Ildong Pharmaceutical Co., Ltd. stock quote today ?
Ildong Pharmaceutical Co., Ltd. stock price is $39900 today.
Is Ildong Pharmaceutical Co., Ltd. stock public?
Yes, Ildong Pharmaceutical Co., Ltd. is a publicly traded company.
Company Profile
- Volume Average 1.09M
- Market Capitalization 1000.43B
- Employee 1.41K
- Headquarters Seoul,US
- IPO Date 2016-08-31
-
Website
https://www.ildong.com 
Ildong Pharmaceutical Co., Ltd. develops, manufactures, and sells pharmaceutical products in South Korea. The company offers active lactic acid bacterial and anti-diarrheal agents, antibiotics, antifungal and antiviral products, anti-histamine drugs, antineoplastic agents, and NSAIDs and analgesics, as well as vitamins, minerals, and nutrients; and drugs for blood circulation, cardiovascular and central nervous system, dental, endocrine and metabolic system, gastrointestinal system, respiratory system, topical preparation, and urogenital system applications. It also provides raw material drugs; health foods and foods; cosmetics; medical devices for scar treatment; and other drugs for treating thick wounds, osteoarthritis, periarthritis of shoulder, and artificial tears, as well as feminine cleanser products. In addition, the company manages licenses and provides contract manufacturing services. It also exports its products to approximately 20 countries worldwide. Ildong Pharmaceutical Co., Ltd. a strategic collaboration with Evotec SE to accelerate the development of various Ildong's proprietary projects through access to Evotec's INDiGO platform. The company was founded in 1941 and is headquartered in Seoul, South Korea.
